Content :
Highlights
2007 FULL-YEAR: Earnings ahead of guidance and a sharp rise in proposed dividend
RESEARCH & DEVELOPMENT: A portfolio of 113 products (1) in development: 47 of which in late stage (Phase IIb / III) and 59 in early stage (pre-clinical / Phase I)
2008 GUIDANCE: Barring major adverse events, sanofi-aventis expects 2008 adjusted EPS excluding selected items (2) to grow around 7%, calculated at constant 2007 euro/dollar parity (1,371).
2007 full year : Earnings ahead of full-year guidance (3)
-
Net sales up 2.8% on a comparable basis (down 1.1% on a reported basis) at €28,052 million
-
Growth of 6.4% in Pharmaceuticals net sales after excluding the impact of generics of Ambien® IR in the United States and Eloxatin® in Europe; 14.5% growth in Vaccines net sales
-
Lantus®: First insulin brand to exceed €2 billion of sales
-
Marked decline in selling and general expenses, with the ratio of selling and general expenses down 1.4 points at 26.9%
-
Business development highlights: signature of alliance agreements with Regeneron, Acambis, Crucell and Oxford Biomedica, and buyout of rights to several of our products in Japan
Fourth quarter 2007
- Net sales down 2.2% on a comparable basis (or 6.0% on a reported basis) at €6,911 million
- Growth of 5.7% in pharmaceuticals net sales after excluding the impact of generics of Ambien® IR in the United States and Eloxatin® in Europe
- Growth in earnings despite the negative effects of the euro/dollar exchange rate and of earlier shipments of influenza vaccines than in 2006
Recent events
Recent events
| February 14, 2008 |
Sanofi-aventis’ SoloSTAR® insulin pen for Lantus and Apidra receives the prestigious GOOD DESIGN Award |
| February 14, 2008 |
Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis |
| February 13, 2008 |
Sanofi Pasteur Files for European Approval of the First Seasonal Influenza Vaccine Delivered by Intradermal Microinjection |
| February 12, 2008 |
Sanofi-aventis enters into Antibody Agreements with Dyax for the fully human monoclonal antibody DX-2240 and "Phage Display Technology" |
| February 4, 2008 |
"My child matters": 25 programmes in 16 countries to fight childhood cancers |
| January 28, 2008 |
Clexane®/Lovenox® approved in Japan |
| January 4, 2008 |
Ambien CR® (zolpidem tartrate extended-release) tablets CIV improved chronic insomnia in patients with co-morbid generalized anxiety disorder |
| January 3, 2008 |
Sanofi Pasteur Enters Agreement with Crucell for Next-generation Biologicals against Rabies |
| December 13, 2007 |
Taxotere®-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy In Early Stage Breast Cancer |
| December 10, 2007 |
New anti-thrombotic compound AVE5026 shows highly significant dose response in TREK phase IIb study |
| December 3, 2007 |
Sanofi-aventis inaugurates first Asian development centre for pharmaceuticals in Goa, India |
References
- 1: as of February 12, 2008
- 2: Adjusted EPS excluding selected items for 2007 was €5.17.
- 3: Adjusted EPS excluding selected items up 13% at a constant 2006 euro/dollar rate (1.25) against guidance of 10% growth
|
